Dravet Syndrome Clinical Trial
Official title:
Expanded Access Use of Stiripentol in Participants With Dravet Syndrome or Epileptic Encephalopathies Associated With Sodium Channel Mutations
This is an expanded access use of Stiripentol in Dravet Syndrome or epileptic encephalopathies associated with sodium channel mutations who have failed other drugs in an effort to give them the best chance at seizure control and quality of life. As a treatment protocol and not a research study, children will only be monitored on a clinical basis for seizure improvement and side effects predominantly by parent and caregiver report.
The initial dose of Stiripentol will be determined by the prescribing neurologist and
titrated up to an initial goal dose of 50 mg/kg/day divided into 2 to 3 doses per day.
Further dose increases by 10-20 mg/kg/day increments up to a max of 100 mg/kg/day or 4000 mg
total daily dose may be necessary for improved seizure control.
Stiripentol is available as gelatin capsules and powder sachets (250 mg, 500 mg). The same
granule formulation (i.e. active, PVP and portion of sodium starch glycolate) used for the
capsule is used in the final powder blend with a few additional excipients. Depending upon
patient weight, the 250 mg or 500 mg formulation will be utilized for each participant.
Caretakers will be queried about common adverse effects including drowsiness, tremor, ataxis,
nausea, anorexia, weight loss, and emesis. Intolerable adverse effects will prompt dose
reduction or withholding medication.
Monitoring of these and other potential AEs will occur during study visits and
participant-initiated telephone calls throughout the study. Safety events and tolerability
will be recorded as adverse events (AE) or serious adverse events (SAE).
Physical examination, weight, vital signs, and laboratory tests (cbc, complete metabolic
panel, and AED levels) will be conducted at baseline and at least every 6 months and as
clinically warranted.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05651204 -
GABA Biomarkers in Dravet Syndrome
|
||
| Withdrawn |
NCT02910297 -
The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy
|
||
| Recruiting |
NCT04462770 -
EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome
|
Phase 2 | |
| Completed |
NCT02896608 -
Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome
|
||
| Withdrawn |
NCT05140122 -
LEONIDaS Caregivers Study
|
||
| Recruiting |
NCT05635266 -
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT02091206 -
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
|
Phase 2 | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Recruiting |
NCT05472389 -
Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome
|
N/A | |
| Recruiting |
NCT05626634 -
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
|
Phase 2 | |
| Recruiting |
NCT01858285 -
Genetics of Epilepsy and Related Disorders
|
||
| Recruiting |
NCT04614506 -
Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome
|
||
| Recruiting |
NCT06118255 -
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
|
Phase 3 | |
| Recruiting |
NCT04611438 -
Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome
|
Phase 3 | |
| Completed |
NCT02091375 -
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
|
Phase 3 | |
| Completed |
NCT05364021 -
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06112275 -
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03254680 -
Turmeric as Treatment in Epilepsy
|
N/A | |
| Terminated |
NCT02187809 -
Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
|
Phase 3 | |
| Withdrawn |
NCT02174094 -
Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
|
Phase 3 |